EVMN
Evommune, Inc.
Evommune, Inc. (EVMN) has 10 SEC Form 4 filings (17 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Jul 10, 2026.
Insiders have net sold $2.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Luis C. Pena
- Employees:48
- HQ:Palo Alto, CA, US
- IPO:2025-11-06
Insider Buying
$146K
reported purchases (SEC code P)
Insider Selling
$2.3M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$472.2M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Financial Officer | Purchase | 1,000 | $13K | Jul 10 | SEC ↗ | |
| Director | Purchase | 10,000 | $133K | Jul 9 | SEC ↗ | |
Drew Janice SuzannFirst filing | Chief of Dev. Operations | Sale | 20,000 | $453K | Jun 25 | SEC ↗ |
| Chief Scientific Officer | Sale | 1,488 | $33K | Jun 25 | SEC ↗ | |
| President & CEO | Sale | 7,438 | $169K | Jun 24 | SEC ↗ | |
Patel Jeegar PravinkumarFirst filing | Chief Scientific Officer | Sale | 16,687 | $379K | Jun 3 | SEC ↗ |
Cohen David EFirst filing | Director | Sale | 6,056 | $123K | Jun 3 | SEC ↗ |
Pena Luis C.First filing | President & CEO | Sale | 16,787 | $382K | Jun 3 | SEC ↗ |
Moss Gregory S.First filing | Chief Business & Legal Officer | Sale | 14,223 | $325K | Jun 2 | SEC ↗ |
Carver KyleFirst filing | Chief Financial Officer | Sale | 18,175 | $415K | Jun 1 | SEC ↗ |
Related companies
Evommune, Inc. is in the Healthcare sector.